Why the study?
Does centrally administered losartan reduce mean arterial pressure in DOCA-salt hypertensive rats?
Does centrally administered losartan reduce mean arterial pressure in DOCA-salt hypertensive rats?
Answers are grounded in this paper and cite their sources.
Central administration of the AT1 receptor antagonist losartan normalizes blood pressure in DOCA-salt hypertensive rats, suggesting brain AT1 receptors play a key role in the development and maintenance of this hypertension model.
To investigate whether brain AT1 receptor stimulation contributes as a hypertensive mechanism to deoxycorticosterone acetate (DOCA)-salt hypertension, losartan (1 mg/4 microL) or artificial cerebrospinal fluid (aCSF) was injected into the lateral cerebral ventricle in conscious control uninephrectomized Wistar rats or rats with DOCA-salt for 2 or 4 weeks, and mean arterial pressure (MAP) and heart rates (HR) were recorded. In rats with DOCA-salt treatment, resting MAP increased to 144+/-6 mmHg after 2 weeks and to 170+/-5 mmHg after 4 weeks versus 115- 120 mmHg in controls. In rats with 2 week DOCA-salt treatment, MAP started declining at 4 hr after intracerebroventricular (icv) injection of losartan, and significant decreases in MAP were found at 18 and 24 hr. In rats with 4 week DOCA-salt treatment, MAP was significantly decreased at 4, 18 and 24 hr. In both groups MAP decreased to that of control rats. In control rats, icv losartan had no effect on MAP and HR. Icv aCSF did not significantly change MAP and HR in either DOCA-salt hypertensive rats or control rats. Normalization of MAP after icv administration of the AT1 receptor antagonist suggests a significant role for brain AT1 receptor stimulation in the development and maintenance of hypertension in the DOCA-salt hypertensive rat model.
No takes yet. Share an insight, caveat, or question.
Park et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: